Cerevel Therapeutics Holdings, Inc. (CERE)
After hours:
| Previous close | 25.62 |
| Open | 25.54 |
| Bid | 25.00 x 800 |
| Ask | 32.75 x 900 |
| Day's range | 25.05 - 26.42 |
| 52-week range | 12.01 - 46.16 |
| Volume | |
| Avg. volume | 399,640 |
| Market cap | 3.724B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.54 |
| Earnings date | 22 Mar 2022 - 28 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 47.25 |
- GlobeNewswire
Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented
Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia Company expects to initiate Phase 2 program for emraclidine in schizophrenia by the middle of 2022, with data expected in the first half of 2024 Phase 1 trial for darigabat in acute anxiety completed; data is expected in the next several weeks Phase 2a data for CVL-871 in dementia-related apathy now expected 1H 2023; delayed from 2H 2022, due in
- GlobeNewswire
Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that Chairperson and Chief Executive Officer Tony Coles, M.D., will present at the upcoming virtual 40th Annual J.P. Morgan Healthcare Conference. Dr. Coles will be joined by Chief Medical Officer Raymond Sanchez, M.D., and Chief Scientific Officer John Renger, Ph.D., for the question-and-answe
- Simply Wall St.
One Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) insider upped their stake by 148% in the previous year
Viewing insider transactions for Cerevel Therapeutics Holdings, Inc.'s ( NASDAQ:CERE ) over the last year, we see that...
